AUA2025: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities
Update: 2025-06-18
Description
AUA2025: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities
CME Available: https://auau.auanet.org/node/43003
At the conclusion of this activity, participants will be able to:
1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.
2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images
3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.
4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.
5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
CME Available: https://auau.auanet.org/node/43003
At the conclusion of this activity, participants will be able to:
1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.
2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images
3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.
4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.
5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.
6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.
ACKNOWLEDGEMENTS:
This educational activity is supported by independent educational grants from:
Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
